The aim of this study was to evaluate the effectiveness of CyberKnife-based stereotactic ablative radiotherapy on prostate cancer lymph node metastases. Our material consisted of 18 patients with 31 metastatic lymph nodes irradiated between 2011 and 2014 using CyberKnife-based stereotactic ablative radiotherapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients were irradiated using fraction dose varied from 6 to 15 Gy (median 10), to the total dose of 24 to 45 Gy (median 30) Irradiated lymph node size varied from 0 4 to 4 0 cm In all, 9 patients had single lymph node metastasis and 9 patients had metastases of 2 to 4 lymph nodes Prostate-specific antigen concentration before radiotherapy varied from 0 01 to 15 58 (mean 6 97; median 4 66) All patients at the time of radiotherapy and follow-up received androgen deprivation therapy Mann-Whitney U, Kaplan-Meier method, and log-rank tests were used in statistical analysis We obtained the following results: after CyberKnife stereotactic ablative radiotherapy, prostate-specific antigen concentration dropped in majority of cases and during the last control varied from 0 00 to 258 00 (median 2 5), and was lower in patients without dissemination to other organs (P = 01) Complete regression was found in 12 lesions, stable disease in 13, and progression in 4 In 7 patients, the dissemination to other organs occurred Our results allow us to conclude that CyberKnife stereotactic ablative radiotherapy of prostate cancer lymph node oligometastases gives good local control and relatively good prostate-specific antigen response
Technology in cancer research & treatment 2015 Jul 24 [Epub ahead of print]
Aleksandra Napieralska, Leszek Miszczyk, Małgorzata Stąpór-Fudzińska
Radiotherapy Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland olanapieralska@gmail com , Radiotherapy Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland , Department of Radiotherapy and Brachytherapy Planning, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland